FY2025 Earnings Forecast for Novavax Issued By HC Wainwright

Key Points

• HC Wainwright analysts predict Novavax will earn $2.89 per share for FY2025, while the current consensus estimate is a loss of ($1.46) per share.
• Novavax reported $0.62 EPS for the last quarter, surpassing estimates, but revenue fell 42.4% year-over-year.
• The stock currently has a market cap of $1.21 billion, with institutional investors owning over 53% of the shares.

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Novavax in a report issued on Thursday, August 28th. HC Wainwright analyst S. Lee expects that the biopharmaceutical company will earn $2.89 per share for the year. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Novavax's Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.06) EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.69. The firm had revenue of $239.24 million for the quarter, compared to the consensus estimate of $149.19 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm's quarterly revenue was down 42.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.99 EPS.

Several other equities research analysts also recently issued reports on NVAX. B. Riley restated a "buy" rating on shares of Novavax in a report on Monday, May 19th. JPMorgan Chase & Co. reduced their target price on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research note on Friday, May 9th. Citigroup began coverage on shares of Novavax in a research note on Tuesday, June 17th. They issued a "sell" rating and a $6.00 price target for the company. Finally, Bank of America reaffirmed an "underperform" rating and issued a $7.00 price target (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $14.29.

Novavax Trading Down 1.5%

NASDAQ:NVAX opened at $7.47 on Monday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 3.28, a price-to-earnings-growth ratio of 0.10 and a beta of 2.68. Novavax has a one year low of $5.01 and a one year high of $15.22. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.34 and a current ratio of 2.36. The business's 50-day simple moving average is $7.40 and its 200 day simple moving average is $7.16.

Institutional Investors Weigh In On Novavax

Several institutional investors and hedge funds have recently made changes to their positions in NVAX. GF Fund Management CO. LTD. bought a new position in Novavax during the fourth quarter worth $27,000. State of Wyoming acquired a new stake in shares of Novavax during the second quarter worth $52,000. Signaturefd LLC lifted its position in shares of Novavax by 47.2% in the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 3,122 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Novavax in the 2nd quarter worth about $73,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Novavax in the 1st quarter valued at about $71,000. 53.04% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.